CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Alemtuzumab

Last Updated: October 1, 2013
Result type: Reports
Project Number: SR0355-000
Product Line: Reimbursement Review

Generic Name: Alemtuzumab

Brand Name: Lemtrada

Manufacturer: Genzyme Canada, a Division of sanofi-aventis Canada Inc.

Therapeutic Area: Multiple sclerosis, relapsing-remitting

Indications: Multiple Sclerosis, relapsing

Submission Type: Initial

Project Status: Withdrawn